Of patients in the solifenacin 5 mg group, 48% elected a dose increase, and 51% of patients in the tolterodine ER group elected a dose increase at four weeks.

Additionally, 24% of 505 patientstreated with tolterodine ER 4 mg once dailyreported dry mouth compared with 8% of507 patients who received placebo. 25,26 Severe dry mouth occurred in only 1% to 5 ...

The AWP for both drugs wasobtained in December of 2004 from Analy-Source, an online vendor of drug pricingdata. 17 The cost for tolterodine ER was basedon Detrol LA ® 4 mg and was assumed to be$3 ...

In patients whose ‘severely bothersome’ OAB symptoms are not relieved by tolterodine ER, 4 mg, solifenacin at either 5 or 10 mg doses was shown to re-duce OAB symptoms and improve symptom ...

New York, November 4, 2004 – Combination therapy with Pfizer Inc's DETROL® LA (tolterodine tartrate extended release capsules) and an alpha blocker, a standard treatment for enlarged prostate ...

Methods: Patients were randomized to placebo, mirabegron 50 or 100 mg, or tolterodine extended release (ER) 4 mg orally, once-daily, for 12 weeks. For the post hoc analysis, the primary patient ...